Aclaris therapeutics announces positive results from phase 1 multiple ascending dose trial of ati-2138, an investigational oral covalent itk/jak3 inhibitor

– preliminary data support progression to phase 2a proof of concept trials in t cell-mediated autoimmune diseases –

ACRS Ratings Summary

ACRS Quant Ranking